The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C.
暂无分享,去创建一个
Wafaa El-Akel | Amr Radwan | Mahasen Mabrouk | Tahany Awad | Naglaa Zayed | W. Doss | Wahid Doss | A. Radwan | M. Mabrouk | N. Zayed | A. Awad | W. El-Akel | T. Awad | Abu Bakr Awad
[1] Dieter Häussinger,et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.
[2] M. Kurosaki,et al. Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors , 2010, Hepatitis research and treatment.
[3] C. Sarrazin,et al. Treatment predictors of a sustained virologic response in hepatitis B and C. , 2008, Journal of hepatology.
[4] J. Bukh,et al. Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: A Danish nationwide cohort study , 2011, BMC infectious diseases.
[5] Andrew H Talal,et al. Hepatocyte proliferation in chronic hepatitis C: correlation with degree of liver disease and serum α‐fetoprotein , 2004, Liver international : official journal of the International Association for the Study of the Liver.
[6] Raymond T Chung,et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. , 2005, Journal of hepatology.
[7] M. Abdel-hamid,et al. Hepatitis C virus (HCV) infection in a community in the nile delta: Population description and HCV prevalence , 2000, Hepatology.
[8] I. Sartori. Early Recognition of Hepatocellular Carcinoma Based on Altered Profiles of Alpha-Fetoprotein: , 1994 .
[9] M. Kurosaki,et al. Sequences in the interferon sensitivity‐determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG‐interferon plus ribavirin: Data mining analysis , 2011, Journal of medical virology.
[10] N. Enomoto,et al. Potential relevance of cytoplasmic viral sensors and related regulators involving innate immunity in antiviral response. , 2008, Gastroenterology.
[11] Wei-Yin Loh,et al. Classification and regression trees , 2011, WIREs Data Mining Knowl. Discov..
[12] J. Ross Quinlan,et al. C4.5: Programs for Machine Learning , 1992 .
[13] Yi-Ching Hsieh,et al. Improved detection of prostate cancer using classification and regression tree analysis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. el-Zayadi,et al. Response of Hepatitis C Genotype-4 Naïve Patients to 24 Weeks of Peg-Interferon-α2b/Ribavirin or Induction-Dose Interferon-α2b/Ribavirin/Amantadine: A Non-Randomized Controlled Study , 2005, The American Journal of Gastroenterology.
[15] I. Takei,et al. Novel statistical classification model of type 2 diabetes mellitus patients for tailor-made prevention using data mining algorithm. , 2002, Journal of epidemiology.
[16] Paul Gray,et al. Introduction to Data Mining and Knowledge Discovery , 1998, Proceedings of the Thirty-First Hawaii International Conference on System Sciences.
[17] Hiroki Ikeda,et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis , 2010, Hepatology research : the official journal of the Japan Society of Hepatology.
[18] A. Way,et al. Egypt Demographic and Health Survey 2000. , 2009 .
[19] Y. Shiratori,et al. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? , 2000, Journal of gastroenterology and hepatology.
[20] K. Shianna,et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients , 2010, AIDS.
[21] T. Asselah,et al. Fibrosis and disease progression in hepatitis C , 2002, Hepatology.
[22] M LeBlanc,et al. A review of tree-based prognostic models. , 1995, Cancer treatment and research.
[23] S. Zeuzem. Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? , 2004, Annals of Internal Medicine.
[24] E. Anderson. Hudson et al. , 1977 .
[25] Ian H. Witten,et al. Data mining: practical machine learning tools and techniques, 3rd Edition , 1999 .
[26] K. Hatakeyama,et al. Prognostic Groups in Colorectal Carcinoma Patients Based on Tumor Cell Proliferation and Classification and Regression Tree (CART) Survival Analysis , 2006, Annals of surgical oncology.
[27] Jiawei Han,et al. Data Mining: Concepts and Techniques , 2000 .
[28] M. Abdel-hamid,et al. Response to pegylated interferon alfa‐2a and ribavirin in chronic hepatitis C genotype 4 , 2009, Journal of medical virology.
[29] A. Amer,et al. Viral kinetic of HCV genotype‐4 during pegylated interferon alpha 2a: ribavirin therapy , 2008, Journal of viral hepatitis.
[30] N. Lim,et al. Clinical Significance of Elevated Alpha-Fetoprotein (AFP) in Patients with Chronic Hepatitis C, but not Hepatocellular Carcinoma , 2004, American Journal of Gastroenterology.
[31] T. Ide,et al. A Decrease in AFP Level Related to Administration of Interferon in Patients with Chronic Hepatitis C and a High Level of AFP , 2006, Digestive diseases and sciences.
[32] Sanaa M Kamal,et al. Hepatitis C genotype 4: What we know and what we don't yet know , 2008, Hepatology.
[33] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[34] Stefan Zeuzem. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? , 2004 .
[35] A. Fontanet,et al. Serum Alpha-Fetoprotein Predicts Treatment Outcome in Chronic Hepatitis C Patients Regardless of HCV Genotype , 2008, PloS one.
[36] J. Gornbein,et al. Phosphorus ans an early predictive factor in patients with acute liver failure1 , 2003, Transplantation.
[37] Stephen L. Chen,et al. The Natural History of Hepatitis C Virus (HCV) Infection , 2006, International journal of medical sciences.
[38] P. Marcellin,et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4 , 2009, Gut.
[39] M. Abdel-hamid,et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C , 2008, Liver international : official journal of the International Association for the Study of the Liver.
[40] J Sunil Rao,et al. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. , 2002, Surgery.
[41] M. Kurosaki,et al. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis , 2011, Journal of Gastroenterology.
[42] Md. Parvez Anwar,et al. 324 Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2B in combination with ribavirin , 2003 .
[43] S. Paul,et al. Discovery of novel targets for multi-epitope vaccines: Screening of HIV-1 genomes using association rule mining , 2009, Retrovirology.
[44] M. Abdel-hamid,et al. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. , 2007, Antiviral therapy.
[45] S. Mauss,et al. Estimating the likelihood of sustained virological response in chronic hepatitis C therapy , 2011, Journal of viral hepatitis.
[46] M. Capobianchi,et al. The Effect of Age on Response to Therapy With Peginterferon α Plus Ribavirin in a Cohort of Patients With Chronic HCV Hepatitis Including Subjects Older Than 65 Yr , 2007, The American Journal of Gastroenterology.
[47] N. Tanaka,et al. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in chronic hepatitis C patients using viral and host factors , 2008, Hepatology.
[48] A. Bhalla,et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.